Azor(TM) Reduces Blood Pressure In Difficult To Treat Special Populations

Daiichi Sankyo, Inc., announced that data presented at the American Society of Hypertension’s Twenty- Third Annual Scientific Meeting (ASH 2008) in New Orleans demonstrated that the powerful combination drug AZOR(TM) (amlodipine and olmesartan medoxomil) safely and effectively helped patients across several major subpopulations lower their blood pressure (BP).

More: continued here

Filed under: Clinical Trials on May 17th, 2008